Risk Stratification to Predict Renal Survival in Anti–Glomerular Basement Membrane Disease

Significance Statement Most patients with anti–glomerular basement membrane (GBM) disease present with rapidly progressive glomerulonephritis, and more than half develop ESKD. Currently, no tools are available to aid in the prognostication or management of this rare disease. In one of the largest assembled cohorts of patients with anti-GBM disease (with 174 patients included in the final analysis), the authors demonstrated that the renal risk score for ANCA-associated vasculitis is transferable to anti-GBM disease and the renal histology is strongly predictive of renal survival and recovery. Stratifying patients according to the percentage of normal glomeruli in the kidney biopsy and the need for RRT at the time of diagnosis improves outcome prediction. Such stratification may assist in the management of anti-GBM disease. Background Prospective randomized trials investigating treatments and outcomes in anti–glomerular basement membrane (anti-GBM) disease are sparse, and validated tools to aid prognostication or management are lacking. Methods In a retrospective, multicenter, international cohort study, we investigated clinical and histologic parameters predicting kidney outcome and sought to identify patients who benefit from rescue immunosuppressive therapy. We also explored applying the concept of the renal risk score (RRS), currently used to predict renal outcomes in ANCA-associated vasculitis, to anti-GBM disease. Results The final analysis included 174 patients (out of a total of 191). Using Cox and Kaplan–Meier methods, we found that the RRS was a strong predictor for ESKD. The 36-month renal survival was 100%, 62.4%, and 20.7% in the low-risk, moderate-risk, and high-risk groups, respectively. The need for renal replacement therapy (RRT) at diagnosis and the percentage of normal glomeruli in the biopsy were independent predictors of ESKD. The best predictor for renal recovery was the percentage of normal glomeruli, with a cut point of 10% normal glomeruli providing good stratification. A model with the predictors RRT and normal glomeruli (N) achieved superior discrimination for significant differences in renal survival. Dividing patients into four risk groups led to a 36-month renal survival of 96.4% (no RRT, N≥10%), 74.0% (no RRT, N<10%), 42.3% (RRT, N≥10%), and 14.1% (RRT, N<10%), respectively. Conclusions These findings demonstrate that the RRS concept is transferrable to anti-GBM disease. Stratifying patients according to the need for RRT at diagnosis and renal histology improves prediction, highlighting the importance of normal glomeruli. Such stratification may assist in the management of anti-GBM disease. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_02_27_JASN0000000000000060.mp3

[1]  V. Tesar,et al.  Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study , 2022, Journal of the American Society of Nephrology : JASN.

[2]  Jie Feng,et al.  Meta-Analytical Accuracy of ANCA Renal Risk Score for Prediction of Renal Outcome in Patients With ANCA-Associated Glomerulonephritis , 2022, Frontiers in Medicine.

[3]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[4]  H. Vrielink,et al.  Analyses of registry data of patients with anti-GBM and antineutrophil cytoplasmatic antibody-associated (ANCA) vasculitis treated with or without therapeutic apheresis. , 2021, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[5]  A. Aouba,et al.  ANCA and anti-glomerular basement membrane double-positive patients: A systematic review of the literature. , 2021, Autoimmunity reviews.

[6]  S. Van Laecke,et al.  Recurrence and Outcome of Anti−Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation , 2021, Kidney international reports.

[7]  D. Geetha,et al.  Keeping Up with the Times: Prognostic Tools in ANCA-Associated Glomerulonephritis. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[8]  J. Mölne,et al.  The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. , 2019, Kidney international.

[9]  D. Annane,et al.  Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients , 2019, Front. Immunol..

[10]  U. Panzer,et al.  Development and validation of a renal risk score in ANCA-associated glomerulonephritis. , 2018, Kidney international.

[11]  R. Wolterbeek,et al.  Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[12]  V. Tesar,et al.  Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients , 2017, Kidney international.

[13]  S. Nasr,et al.  The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. , 2016, Kidney international.

[14]  K. Farrington,et al.  Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Gary S Collins,et al.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement , 2015, BMC Medicine.

[16]  David W. Johnson,et al.  Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. , 2013, Kidney international.

[17]  A. Salama,et al.  Update on antiglomerular basement membrane disease , 2011, Current opinion in rheumatology.

[18]  Ming-hui Zhao,et al.  Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. , 2009, Kidney international.

[19]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[20]  L. Revert,et al.  Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. , 1991, Clinical nephrology.

[21]  D. Jayne,et al.  Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. , 1990, Kidney international.

[22]  V. Schuster,et al.  Coexistent Wegener's granulomatosis and anti-glomerular basement membrane disease. , 1987, Human pathology.